Diabetes and Metabolism Journal

Korean Diabetes Association (대한당뇨병학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711-7)

  • Patoulias, Dimitrios (Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki) ;
  • Doumas, Michael (Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki)
  • Published : 2019.12.30
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Kong SH, Koo BK, Moon MK. Effects of dapagliflozin on endothelial function, renal injury markers, and glycemic control in drug-naive patients with type 2 diabetes mellitus. Diabetes Metab J 2019;43:711-7. https://doi.org/10.4093/dmj.2018.0208
  2. Avogaro A, Fadini GP, Gallo A, Pagnin E, de Kreutzenberg S. Endothelial dysfunction in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 2006;16 Suppl 1:S39-45. https://doi.org/10.1016/j.numecd.2005.10.015
  3. Baqar S, Straznicky NE, Lambert G, Kong YW, Dixon JB, Jerums G, Ekinci EI, Lambert E. Comparison of endothelial function and sympathetic nervous system activity along the glucose continuum in individuals with differing metabolic risk profiles and low dietary sodium intake. BMJ Open Diabetes Res Care 2019;7:e000606. https://doi.org/10.1136/bmjdrc-2018-000606
  4. van Sloten TT, Henry RM, Dekker JM, Nijpels G, Unger T, Schram MT, Stehouwer CD. Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the Hoorn study. Hypertension 2014;64:1299-305. https://doi.org/10.1161/HYPERTENSIONAHA.114.04221
  5. Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K, Yoshida A, Jinnouchi K, Nishimura H, Suzuki T, Miyamoto F, Kajiwara K, Jinnouchi T. The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus. Intern Med 2018;57:2147-56. https://doi.org/10.2169/internalmedicine.0701-17
  6. Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, Hirose T. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol 2017;16:84. https://doi.org/10.1186/s12933-017-0564-0
  7. Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, Bruno RM. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol 2017;16:138. https://doi.org/10.1186/s12933-017-0621-8
  8. Ott C, Jumar A, Striepe K, Friedrich S, Karg MV, Bramlage P, Schmieder RE. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol 2017;16:26. https://doi.org/10.1186/s12933-017-0510-1
  9. Wijkman M, Lanne T, Ostgren CJ, Nystrom FH. Aortic pulse wave velocity predicts incident cardiovascular events in patients with type 2 diabetes treated in primary care. J Diabetes Complications 2016;30:1223-8. https://doi.org/10.1016/j.jdiacomp.2016.06.008
  10. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380:347-57. https://doi.org/10.1056/NEJMoa1812389